Activation of inflammatory pathways such as toll-like receptor (TLR) signaling, of which Gram-negative lipopolysaccharide (LPS) is a TLR-4 ligand, can lead to inflammation-driven cancer progression34–36. This evidence concerns the gene TLR4 and cancer.